How  ||| S:0 E:4 ||| WRB
to  ||| S:4 E:7 ||| TO
treat  ||| S:7 E:13 ||| VB
a  ||| S:13 E:15 ||| DT
home  ||| S:15 E:20 ||| NN
cancer  ||| S:20 E:27 ||| NN
patient  ||| S:27 E:35 ||| NN
when  ||| S:35 E:40 ||| WRB
the  ||| S:40 E:44 ||| DT
patient  ||| S:44 E:52 ||| NN
encountered  ||| S:52 E:64 ||| VBD
with  ||| S:64 E:69 ||| IN
delirium  ||| S:69 E:78 ||| JJ
symptom  ||| S:78 E:86 ||| NN
It  ||| S:86 E:89 ||| PRP
has  ||| S:89 E:93 ||| VBZ
been  ||| S:93 E:98 ||| VBN
5  ||| S:98 E:100 ||| CD
years  ||| S:100 E:106 ||| NNS
since  ||| S:106 E:112 ||| IN
the  ||| S:112 E:116 ||| DT
passage  ||| S:116 E:124 ||| NN
of  ||| S:124 E:127 ||| IN
the  ||| S:127 E:131 ||| DT
Basic  ||| S:131 E:137 ||| NNP
Act  ||| S:137 E:141 ||| NNP
on  ||| S:141 E:144 ||| IN
Countermeasures  ||| S:144 E:160 ||| NNP
against  ||| S:160 E:168 ||| IN
Cancer  ||| S:168 E:175 ||| NNP
and  ||| S:175 E:179 ||| CC
the  ||| S:179 E:183 ||| DT
Promotion  ||| S:183 E:193 ||| NNP
of  ||| S:193 E:196 ||| IN
Cancer  ||| S:196 E:203 ||| NNP
Countermeasures ||| S:203 E:218 ||| NNP
.  ||| S:218 E:220 ||| .
In  ||| S:220 E:223 ||| IN
2012 ||| S:223 E:227 ||| CD
,  ||| S:227 E:229 ||| ,
the  ||| S:229 E:233 ||| DT
early  ||| S:233 E:239 ||| JJ
stage  ||| S:239 E:245 ||| NN
of  ||| S:245 E:248 ||| IN
cancer  ||| S:248 E:255 ||| NN
treatment  ||| S:255 E:265 ||| NN
was  ||| S:265 E:269 ||| VBD
desired  ||| S:269 E:277 ||| VBN
based  ||| S:277 E:283 ||| VBN
on  ||| S:283 E:286 ||| IN
the  ||| S:286 E:290 ||| DT
revision  ||| S:290 E:299 ||| NN
of  ||| S:299 E:302 ||| IN
these  ||| S:302 E:308 ||| DT
master  ||| S:308 E:315 ||| NN
plans  ||| S:315 E:321 ||| NNS
for  ||| S:321 E:325 ||| IN
all  ||| S:325 E:329 ||| DT
cancer  ||| S:329 E:336 ||| NN
patients  ||| S:336 E:345 ||| NNS
as  ||| S:345 E:348 ||| IN
well  ||| S:348 E:353 ||| RB
as  ||| S:353 E:356 ||| IN
their  ||| S:356 E:362 ||| PRP$
families ||| S:362 E:370 ||| NNS
.  ||| S:370 E:372 ||| .
One  ||| S:372 E:376 ||| CD
third  ||| S:376 E:382 ||| JJ
of  ||| S:382 E:385 ||| IN
the  ||| S:385 E:389 ||| DT
1  ||| S:389 E:391 ||| CD
million  ||| S:391 E:399 ||| CD
annual  ||| S:399 E:406 ||| JJ
deaths  ||| S:406 E:413 ||| NNS
were  ||| S:413 E:418 ||| VBD
caused  ||| S:418 E:425 ||| VBN
by  ||| S:425 E:428 ||| IN
cancer  ||| S:428 E:435 ||| NN
in  ||| S:435 E:438 ||| IN
Japan ||| S:438 E:443 ||| NNP
,  ||| S:443 E:445 ||| ,
and  ||| S:445 E:449 ||| CC
predicted  ||| S:449 E:459 ||| VBD
that  ||| S:459 E:464 ||| IN
the  ||| S:464 E:468 ||| DT
cancer  ||| S:468 E:475 ||| NN
mortality  ||| S:475 E:485 ||| NN
ratio  ||| S:485 E:491 ||| NN
has  ||| S:491 E:495 ||| VBZ
been  ||| S:495 E:500 ||| VBN
increasing  ||| S:500 E:511 ||| VBG
in  ||| S:511 E:514 ||| IN
trend ||| S:514 E:519 ||| NN
.  ||| S:519 E:521 ||| .
Less  ||| S:521 E:526 ||| RBR
than  ||| S:526 E:531 ||| IN
10 ||| S:531 E:533 ||| CD
%  ||| S:533 E:535 ||| NN
of  ||| S:535 E:538 ||| IN
the  ||| S:538 E:542 ||| DT
end-of-life  ||| S:542 E:554 ||| JJ
stage  ||| S:554 E:560 ||| NN
cancer  ||| S:560 E:567 ||| NN
patients  ||| S:567 E:576 ||| NNS
who  ||| S:576 E:580 ||| WP
prefer  ||| S:580 E:587 ||| VBP
to  ||| S:587 E:590 ||| TO
die  ||| S:590 E:594 ||| VB
at  ||| S:594 E:597 ||| IN
home  ||| S:597 E:602 ||| RB
fulfill  ||| S:602 E:610 ||| VB
their  ||| S:610 E:616 ||| PRP$
desire  ||| S:616 E:623 ||| NN
causing  ||| S:623 E:631 ||| VBG
a  ||| S:631 E:633 ||| DT
lot  ||| S:633 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
problems ||| S:640 E:648 ||| NNS
.  ||| S:648 E:650 ||| .
In  ||| S:650 E:653 ||| IN
order  ||| S:653 E:659 ||| NN
to  ||| S:659 E:662 ||| TO
solve  ||| S:662 E:668 ||| VB
the  ||| S:668 E:672 ||| DT
problems ||| S:672 E:680 ||| NNS
,  ||| S:680 E:682 ||| ,
the  ||| S:682 E:686 ||| DT
importance  ||| S:686 E:697 ||| NN
of  ||| S:697 E:700 ||| IN
medical  ||| S:700 E:708 ||| JJ
treatment  ||| S:708 E:718 ||| NN
by  ||| S:718 E:721 ||| IN
a  ||| S:721 E:723 ||| DT
team  ||| S:723 E:728 ||| NN
consisted  ||| S:728 E:738 ||| VBD
of  ||| S:738 E:741 ||| IN
multi  ||| S:741 E:747 ||| JJ
-disciplinary  ||| S:747 E:761 ||| JJ
professionals  ||| S:761 E:775 ||| NNS
has  ||| S:775 E:779 ||| VBZ
been  ||| S:779 E:784 ||| VBN
sought  ||| S:784 E:791 ||| VBN
out ||| S:791 E:794 ||| RP
.  ||| S:794 E:796 ||| .
We  ||| S:796 E:799 ||| PRP
have  ||| S:799 E:804 ||| VBP
erected  ||| S:804 E:812 ||| VBN
palliative  ||| S:812 E:823 ||| JJ
care  ||| S:823 E:828 ||| NN
team  ||| S:828 E:833 ||| NN
and  ||| S:833 E:837 ||| CC
cancer  ||| S:837 E:844 ||| NN
consulting  ||| S:844 E:855 ||| NN
support  ||| S:855 E:863 ||| NN
center  ||| S:863 E:870 ||| NN
in  ||| S:870 E:873 ||| IN
our  ||| S:873 E:877 ||| PRP$
hospital  ||| S:877 E:886 ||| NN
to  ||| S:886 E:889 ||| TO
help  ||| S:889 E:894 ||| VB
the  ||| S:894 E:898 ||| DT
patient  ||| S:898 E:906 ||| NN
and  ||| S:906 E:910 ||| CC
their  ||| S:910 E:916 ||| PRP$
family  ||| S:916 E:923 ||| NN
since  ||| S:923 E:929 ||| IN
2009 ||| S:929 E:933 ||| CD
.  ||| S:933 E:935 ||| .
The  ||| S:935 E:939 ||| DT
contents  ||| S:939 E:948 ||| NNS
of  ||| S:948 E:951 ||| IN
the  ||| S:951 E:955 ||| DT
consulting  ||| S:955 E:966 ||| NN
subjects  ||| S:966 E:975 ||| NNS
were  ||| S:975 E:980 ||| VBD
varied  ||| S:980 E:987 ||| VBN
and  ||| S:987 E:991 ||| CC
wide ||| S:991 E:995 ||| JJ
,  ||| S:995 E:997 ||| ,
as  ||| S:997 E:1000 ||| IN
we  ||| S:1000 E:1003 ||| PRP
have  ||| S:1003 E:1008 ||| VBP
reported  ||| S:1008 E:1017 ||| VBN
in  ||| S:1017 E:1020 ||| IN
the  ||| S:1020 E:1024 ||| DT
21st  ||| S:1024 E:1029 ||| JJ
Japan  ||| S:1029 E:1035 ||| NNP
Society  ||| S:1035 E:1043 ||| NNP
for  ||| S:1043 E:1047 ||| IN
Home  ||| S:1047 E:1052 ||| NNP
Therapy  ||| S:1052 E:1060 ||| NNP
Research ||| S:1060 E:1068 ||| NNP
( ||| S:1068 E:1069 ||| -LRB-
2010 ||| S:1069 E:1073 ||| CD
) ||| S:1073 E:1074 ||| -RRB-
.  ||| S:1074 E:1076 ||| .
In  ||| S:1076 E:1079 ||| IN
case  ||| S:1079 E:1084 ||| NN
of  ||| S:1084 E:1087 ||| IN
the  ||| S:1087 E:1091 ||| DT
cancer  ||| S:1091 E:1098 ||| NN
patient  ||| S:1098 E:1106 ||| NN
who  ||| S:1106 E:1110 ||| WP
displayed  ||| S:1110 E:1120 ||| VBD
with  ||| S:1120 E:1125 ||| IN
delirium  ||| S:1125 E:1134 ||| JJ
symptom ||| S:1134 E:1141 ||| NN
,  ||| S:1141 E:1143 ||| ,
for  ||| S:1143 E:1147 ||| IN
instance ||| S:1147 E:1155 ||| NN
,  ||| S:1155 E:1157 ||| ,
there  ||| S:1157 E:1163 ||| EX
were  ||| S:1163 E:1168 ||| VBD
many  ||| S:1168 E:1173 ||| JJ
occasions  ||| S:1173 E:1183 ||| NNS
we  ||| S:1183 E:1186 ||| PRP
had  ||| S:1186 E:1190 ||| VBD
to  ||| S:1190 E:1193 ||| TO
stop  ||| S:1193 E:1198 ||| VB
the  ||| S:1198 E:1202 ||| DT
home  ||| S:1202 E:1207 ||| NN
medical  ||| S:1207 E:1215 ||| JJ
treatment ||| S:1215 E:1224 ||| NN
.  ||| S:1224 E:1226 ||| .
So  ||| S:1226 E:1229 ||| RB
we  ||| S:1229 E:1232 ||| PRP
studied  ||| S:1232 E:1240 ||| VBD
how  ||| S:1240 E:1244 ||| WRB
to  ||| S:1244 E:1247 ||| TO
treat  ||| S:1247 E:1253 ||| VB
a  ||| S:1253 E:1255 ||| DT
home  ||| S:1255 E:1260 ||| NN
cancer  ||| S:1260 E:1267 ||| NN
patient  ||| S:1267 E:1275 ||| NN
when  ||| S:1275 E:1280 ||| WRB
the  ||| S:1280 E:1284 ||| DT
patient  ||| S:1284 E:1292 ||| NN
encountered  ||| S:1292 E:1304 ||| VBD
with  ||| S:1304 E:1309 ||| IN
delirium  ||| S:1309 E:1318 ||| JJ
symptom ||| S:1318 E:1325 ||| NN
.  ||| S:1325 E:1327 ||| .
